Janux Therapeutics, Inc. $JANX Shares Purchased by FNY Investment Advisers LLC

FNY Investment Advisers LLC boosted its stake in Janux Therapeutics, Inc. (NASDAQ:JANX) by 111.8% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 5,210 shares of the company’s stock after purchasing an additional 2,750 shares during the period. FNY Investment Advisers LLC’s holdings in Janux Therapeutics were worth $120,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in JANX. GAMMA Investing LLC increased its holdings in Janux Therapeutics by 1,574.0% in the 1st quarter. GAMMA Investing LLC now owns 1,674 shares of the company’s stock valued at $45,000 after purchasing an additional 1,574 shares during the last quarter. US Bancorp DE boosted its position in Janux Therapeutics by 2,402.9% in the 1st quarter. US Bancorp DE now owns 1,727 shares of the company’s stock valued at $47,000 after buying an additional 1,658 shares during the period. KBC Group NV purchased a new position in Janux Therapeutics in the 1st quarter valued at approximately $66,000. Exchange Traded Concepts LLC boosted its position in Janux Therapeutics by 20.4% in the 1st quarter. Exchange Traded Concepts LLC now owns 4,043 shares of the company’s stock valued at $109,000 after buying an additional 686 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Janux Therapeutics by 26.4% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,125 shares of the company’s stock valued at $192,000 after buying an additional 1,488 shares during the period. Institutional investors and hedge funds own 75.39% of the company’s stock.

Janux Therapeutics Trading Down 1.8%

Janux Therapeutics stock opened at $26.34 on Thursday. The stock has a market cap of $1.58 billion, a P/E ratio of -14.63 and a beta of 2.82. The company has a fifty day simple moving average of $24.32 and a 200-day simple moving average of $25.29. Janux Therapeutics, Inc. has a 12-month low of $21.73 and a 12-month high of $71.71.

Janux Therapeutics (NASDAQ:JANX) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.07). As a group, sell-side analysts forecast that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have commented on JANX. Barclays began coverage on shares of Janux Therapeutics in a research report on Wednesday, September 17th. They issued an “overweight” rating and a $47.00 price target for the company. Guggenheim began coverage on shares of Janux Therapeutics in a research report on Wednesday, September 3rd. They issued a “buy” rating and a $72.00 price target for the company. Piper Sandler began coverage on shares of Janux Therapeutics in a research report on Monday, August 18th. They issued an “overweight” rating and a $42.00 price target for the company. Truist Financial began coverage on shares of Janux Therapeutics in a research report on Wednesday, September 10th. They issued a “buy” rating and a $100.00 price target for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Janux Therapeutics in a research report on Wednesday, October 8th. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Janux Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $78.31.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.